Lexicon Pharmaceuticals (LXRX)

• Market cap: $264M
• 1 day: 9.27%
• 5 days: 9.45%
• 1 month: 58.59%
• 3 months: -10.81%
• 6 months: -62.52%
• Year to date: -5.96%
• 1 year: -52.55%
• 5 years: -61.33%
• 10 years: -89.56%
• Sector: Healthcare
• Industry: Biotechnology

About: Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Employees: 103

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

236% more call options, than puts

Call options by funds: $547K | Put options by funds: $163K

88% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 24

2.5% more ownership

Funds ownership: 79.84% [Q3] → 82.34% (+2.5%) [Q4]

8% less funds holding

Funds holding: 137 [Q3] → 126 (-11) [Q4]

29% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 34

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

51% less capital invested

Capital invested by funds: $453M [Q3] → $220M (-$233M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1 37% upside
• Avg. target: $3.67 402% upside
• High target: $6 721% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 89 / 416 met price target	447% upside $4	Buy Reiterated	28 Mar 2025
Piper Sandler Yasmeen Rahimi 25% 1-year accuracy 6 / 24 met price target	721% upside $6	Overweight Maintained	7 Mar 2025
Leerink Partners Roanna Ruiz 33% 1-year accuracy 3 / 9 met price target	37% upside $1	Market Perform Downgraded	4 Mar 2025